Curi Wealth Management LLC Has $6.80 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Curi Wealth Management LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,805 shares of the medical research company's stock after selling 1,668 shares during the quarter. Curi Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $6,797,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Northwest Financial Advisors acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Raleigh Capital Management Inc. increased its position in Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company's stock worth $41,000 after buying an additional 27 shares during the period. Cedar Mountain Advisors LLC increased its position in Thermo Fisher Scientific by 107.0% in the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company's stock worth $47,000 after buying an additional 46 shares during the period. Pacific Capital Wealth Advisors Inc. bought a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $51,000. Finally, Financial Connections Group Inc. bought a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $53,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $564.72, for a total transaction of $5,647,200.00. Following the completion of the transaction, the chief executive officer now directly owns 128,485 shares in the company, valued at $72,558,049.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,547 shares of the business's stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the transaction, the chief executive officer now owns 43,608 shares of the company's stock, valued at approximately $24,011,436.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $564.72, for a total value of $5,647,200.00. Following the completion of the sale, the chief executive officer now directly owns 128,485 shares of the company's stock, valued at approximately $72,558,049.20. The disclosure for this sale can be found here. Insiders sold 37,547 shares of company stock worth $21,541,269 over the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent analyst reports. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating on the stock in a research report on Thursday, April 25th. Deutsche Bank Aktiengesellschaft boosted their price objective on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a "buy" rating in a research report on Thursday, April 25th. The Goldman Sachs Group boosted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a "buy" rating in a research report on Wednesday, April 10th. Royal Bank of Canada boosted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an "outperform" rating in a research report on Thursday, February 1st. Finally, JPMorgan Chase & Co. boosted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $607.35.

Thermo Fisher Scientific Trading Up 0.7 %

NYSE TMO traded up $4.10 on Tuesday, reaching $594.80. The company had a trading volume of 1,036,290 shares, compared to its average volume of 1,534,697. The stock's 50 day moving average is $576.44 and its 200-day moving average is $538.94. The stock has a market cap of $227.05 billion, a price-to-earnings ratio of 38.15, a PEG ratio of 2.46 and a beta of 0.80. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Equities analysts predict that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a $0.39 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific's dividend payout ratio is 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.